Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, describes the development of LY3009120 for patients with chronic myeloid leukemia (CML) resistant to tyrosine kinase inhibitors (TKIs) via BCR-ABL1 mutations. Ponatinib and asciminib is a potential regimen to resensitize patients to TKIs but is not feasible due to the high toxicity of the required ponatinib dose. LY3009120 was identified as a candidate molecule that when paired with asciminib, can target BCR-ABL1 mutations. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
